anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The hypoxia-inducible factor (HIF) is considered key in the transcriptional response to low oxygen. Yet, the role of HIF in the absence of oxygen (anoxia) and in preparation for reoxygenation remains unclear. Recent studies suggest that mounting a HIF response may be counterproductive for anoxia survival. We here studied one of the champions of anoxia survival, the crucian carp (Carassius carassius), and hypothesized that expression of prolyl hydroxylase domains (PHDs; the upstream regulators of HIF) are upregulated to circumvent an energy-costly activation of HIF in anoxia and to prepare for reoxygenation. We measured whole brain mRNA and protein levels of the three isoforms PHD1, PHD2, and PHD3, coded for by multiple paralogs of the genes egln2, egln1, and egln3, using quantitative PCR and Western blotting in the brain of crucian carps exposed to 5 days normoxia or anoxia, and 5 days anoxia followed by 3 or 24 h of reoxygenation. The mRNA levels of most egln paralogs were increased in anoxia and upon reoxygenation, with egln3 showing the largest increase in mRNA level (up to 17-fold) and highest relative mRNA abundance (up to 75% of expressed egln). The protein level of all PHDs was maintained in anoxia and increased upon reoxygenation. We then explored PHD distribution in different brain regions and found PHD immunoreactivity to be associated with axonal branches and showing region-specific changes during anoxia-reoxygenation. Our results support an overall upregulation of egln under prolonged anoxia and PHDs upon reoxygenation in crucian carp, likely aimed at suppressing HIF responses, although regional differences are apparent in such a complex organ as the brain.NEW & NOTEWORTHY We report a profound upregulation of most egln paralog mRNA levels in anoxia and upon reoxygenation, with egln3ii showing the largest, a 17-fold increase, and highest relative mRNA abundance. The relative abundance of prolyl hydroxylase domain (PHD) proteins was maintained during anoxia and increased at reoxygenation. PHD immunoreactivity was localized to axonal branches with region-specific changes during anoxia-reoxygenation. These dynamic and regional changes in crucian carp, champion of anoxia tolerance, are most likely adaptive and call for further mechanistic studies.
A patient monitoring device 230 includes first and second sensors for measuring a physical parameter of the patient 220 at two separate locations. The outputs of the sensors are used to determine the physical parameter and calculate a priority score which is displayed on a display 234. The device 230 may be worn on a patient’s forehead 221, and may be used for casualty triage. The sensors may be pulse oximetry sensors in compartments (1213, fig 12a) on opposite sides of the subject’s forehead or fingertip PPG sensors (1530, 1532, fig 15b). There may be a control panel 231 to allow a clinician to input observations. The patient priority score may be displayed as a red, yellow or green LED 233 on the device. The priority score may be continuously updated based on the measured data. The sensor outputs may be communicated to a server and displayed on a Clinician Control Dashboard (fig 8a) to rank patients in a patient priority table.
OBJECTIVE: Epilepsy management employs self-reported seizure diaries, despite evidence of seizure underreporting. Wearable and implantable seizure detection devices are now becoming more widely available. There are no clear guidelines about what levels of accuracy are sufficient. This study aimed to simulate clinical use cases and identify the necessary level of accuracy for each.
METHODS: Using a realistic seizure simulator (CHOCOLATES), a ground truth was produced, which was then sampled to generate signals from simulated seizure detectors of various capabilities. Five use cases were evaluated: (1) randomized clinical trials (RCTs), (2) medication adjustment in clinic, (3) injury prevention, (4) sudden unexpected death in epilepsy (SUDEP) prevention, and (5) treatment of seizure clusters. We considered sensitivity (0%-100%), false alarm rate (FAR; 0-2/day), and device type (external wearable vs. implant) in each scenario.
RESULTS: The RCT case was efficient for a wide range of wearable parameters, though implantable devices were preferred. Lower accuracy wearables resulted in subtle changes in the distribution of patients enrolled in RCTs, and therefore higher sensitivity and lower FAR values were preferred. In the clinic case, a wide range of sensitivity, FAR, and device type yielded similar results. For injury prevention, SUDEP prevention, and seizure cluster treatment, each scenario required high sensitivity and yet was minimally influenced by FAR.
SIGNIFICANCE: The choice of use case is paramount in determining acceptable accuracy levels for a wearable seizure detection device. We offer simulation results for determining and verifying utility for specific use case and specific wearable parameters.
Participants will receive CloSYS unflavored rinse containing 0.1% stabilized chlorine dioxide (sodium chlorite) in an aqueous solution for 3 weeks,. After a washout period of 2 weeks, they will then receive Placebo unflavored rinse containing containing NO 0.1% stabilized chlorine dioxide for 3 weeks.
Cerene was approved by the FDA in March 2019 for endometrial cryoablation in premenopausal women with heavy menstrual bleeding due to benign causes for whom child bearing is complete. The primary objective of the Progress registry is to bridge the gap between clinical results and outcomes reported during the pivotal study of Cerene (the CLARITY Study) and those observed during its real-world use. The Progress registry will gather prospective, observational data on up to 300 women that underwent a Cerene treatment. Patients and physicians will complete surveys. Surveys will include patient demographic characteristics and quality of life measures at baseline, procedural details, and post-operative clinical outcomes and quality of life measures.

Patient participation is expected to last approximately 13 months, from the time of patient enrollment to 12 months post treatment. The study will end after the last participating patient in completes her 12 month visit.
In ZOLGENSMA clinical trials, patients were required to have baseline anti-AAV9 antibody titers of ≤ 1:50, measured using an enzyme-linked immunosorbent assay (ELISA). Evidence of prior exposure to AAV9 was uncommon. The safety and efficacy of ZOLGENSMA in patients with anti-AAV9 antibody titers above 1:50 have not been evaluated. Perform baseline testing for the presence of anti-AAV9 antibodies prior to ZOLGENSMA infusion. Retesting may be performed if anti-AAV9 antibody titers are reported as > 1:50 [see Dosage and Administration (2.1, 2.3)].

Following ZOLGENSMA infusion, increases from baseline in anti-AAV9 antibody titers occurred in all patients. In Study 2, anti-AAV9 antibody titers reached at least 1:102,400 in every patient, and titers exceeded 1:819,200 in most patients. Re-administration of ZOLGENSMA in the presence of high anti-AAV9 antibody titer has not been evaluated.
Patients will be randomized to treatment or placebo arms preoperatively. In our placebo arm of pregnant patients with suspected placenta accreta, patients will receive plain normal saline in a 50 cc bag identical to the preparation of study drug immediately after delivery of the infant.
Music therapy sessions. Planned 1:1 within acute neurology/rehabilitation patient rooms, or private rooms by a qualified music therapist once weekly and/or group music therapy sessions maximum 6-8 patients for less than or equal to one hour. Music therapy includes a variety of techniques used to target mood, pain, socialisation, expressive speech, attention/cognitive or sensorimotor functional goals.
FIELD: medicine, chemical-pharmaceutical industry. SUBSTANCE: invention relates to the development and production of antiscabietic medicinal agents. Invention relates to a medicinal agent as an ointment. The composition comprises benzyl benzoate as an active component, emulsifying agent and water being triethanolamine stearate as an emulsifying agent is formed as a result of reaction of thermostable triethanolamine and stearic acid that are components of an ointment and the composition comprises polyethylene oxide-400 additionally and all components are taken in the definite ratio. A medicinal agent is suitable in using, it retains on skin for 4-5 days, shows high curative effect and stability for a long time. EFFECT: enhanced effectiveness of drug, improved properties. 2 tbl
Cancer immunotherapy deploys the host's immune system to recognize and attack cancerous tumors. However, the efficacy is greatly restricted by the immunosuppressive (i.e., immunologically cold) tumor microenvironment (TME). In-situ cryo-immune engineering (ICIE) strategy turns the TME from immunologically “cold” into “hot”. In particular, after the ICIE treatment, the ratio of the CD8 +  cytotoxic T cells to the immunosuppressive regulatory T cells is increased in primary tumors and distant tumors without freezing. The ICIE treatment causes “frostbite” of tumor with cold-responsive nanoparticles that target cancer cells. This rapidly releases both anticancer drug(s) and PD-L1 silencing siRNA into the cytosol. This ICIE treatment leads to potent immunogenic cell death, which promotes maturation of dendritic cells and activation of CD8 +  cytotoxic T cells and memory T cells. Collectively, ICIE enables an efficient and durable way to leverage the immune system for combating cancer and its metastasis.
OBJECTIVE: This study aims to investigate the anatomical variations in femoral vasculature and evaluate the clinical value of ultrasound-guided femoral vein puncture in catheter ablation procedures.
METHODS: In this retrospective analysis conducted from January 2023 to March 2023, we examined data from patients who underwent catheter ablation with ultrasound-guided femoral venipuncture. We evaluated the anatomy of the femoral vasculature at both high and low inguinal levels. Based on the relationship between the femoral vein and artery, we classified the anatomy into four types: Type I (vein parallel to artery without overlap), Type II (vein medial to artery with lumen overlap ≤50%), Type III (vein posterior to artery with lumen overlap > 50%), and Type IV (vein lateral to artery). Additionally, we assessed procedure-related vascular complications that required interventions or prolonged hospital stays.
RESULTS: A total of 254 patients were included in this study. At the upper inguinal level, most cases (92.5%) exhibited Type II, followed by Type I (6.5%), while Type III (0.6%) and IV (0.4%) were less common. At the lower inguinal level, Type II accounted for 70.7%, there was a significantly higher proportion of Type III (23.4%) and Type IV (5.9%). The overall complication rate was 0.4%, no pseudoaneurysm or hematoma was observed in our study.
CONCLUSION: Our study revealed significant anatomical variations in the relationship between the femoral vein and femoral artery. Ultrasound-guided femoral venipuncture significantly reduced vascular complication rate, making it a valuable tool for guiding puncture procedures.
Participants undergo upper GI endoscopy with endoscopic mucosal resection (EMR) and/or radiofrequency ablation (RFA) of esophageal squamous dysplasia (ESD). After initial therapy participants undergo repeat endoscopy every 3 months for a year, with re-biopsy and re-treatment of residual ESD as appropriate.
The present disclosure relates to antagonists that target or inhibit Serine/Arginine Rich Splicing Factor 1 (SRSF1). A viral vector, such as an AAV, is disclosed which comprises a non-expressed sequence (e.g. a stuffer sequence) and a nucleic acid encoding an antagonist of SRSF1 which is operably linked to a promotor. The antagonist may be an inhibitory RNA, such as shRNA, miRNA, antisense RNA or may be an inhibitory peptide which is, for example, fused to a cell penetrating peptide, CPP. The viral vector may be formulated as a pharmaceutical. Also disclosed are an inhibitory RNA to SRSF1, a cell penetrating peptide antagonist of SRSF1 and an agent comprising an inhibitory RNA to SRSF1, each of which may be formulated into a pharmaceutical composition. The SRSF1 antagonists may be used in the treatment of neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, motor neurone disease, MND), sporadic Amyotrophic Lateral Sclerosis which is not caused by a pathological C9ORF72 hexanucleotide repeat expansion, sporadic frontotemporal dementia (FTD) or Fragile X-associated tremor/ataxia syndrome (FXTAS).
The "NOVOS Core" supplement is a commercially available product and has 12 ingredients. It was developed and is provided together with the placebo by AgeLess Sciences LLC, a Public Benefit Corporation.
The objective management of chronic disease. A kind of health management system arranged multiple object modules (14) that comprise. Each object module comprises one or more content sessions (16,18,71,72,73,74,120,122,126,140,148), and these one or more content sessions cooperate mutually to realize health management goal. User interface (30) is configured to rendering content session. At least one feedback network (30,32,36,38) provides at least one input, and this input represents the user answer that the content session to being presented by user interface is made. Ao content flow engine (42) is configured to the order that presents based at least one input and content flow rule (44,46,48) Control the content session.
PROBLEM TO BE SOLVED: To make it possible to obtain still picture images such as fundus oculi images turned into high picture quality in medial institutions, etc. at lower cost than conventionally possible.SOLUTION: A terminal device transmits search information to a server device via a network. This search information includes information for identifying a moving image and sometimes further includes information for identifying a processing program as well. The server device comprises an image processing unit which generates still image data from the moving image data stored in a storage unit and an image transmission unit which transmits the generated still image data to the terminal device. The image processing unit permits a processing program to be dynamically altered or added. The server device transmits still image data generated from prescribed moving image data corresponding to the search information by processing it with a prescribed processing program to the terminal device. Each terminal device can obtain high picture quality still image data based on the latest processing algorithm without having to process images for themselves.
BACKGROUND: Pre-frailty is associated with increased healthcare utilization. Over the past decade, public health interventions such as community-based exercises to target pre-frailty have been increasingly studied. However, the effects of community-based exercises on clinical outcome measures amongst community-dwelling older adults with pre-frailty remain unclear. This review aims to better understand the effects of community-based exercise on physical function, cognition, quality of life and frailty status in community-dwelling pre-frail older adults. A secondary objective was to investigate the optimal exercise parameters on clinical outcomes.
METHODS: Searches of MEDLINE, CINAHL, Google Scholar and Web of Science databases were conducted. Articles were included if they were randomized controlled trials (RCTs), and excluded if the participants consist of less than 50% pre-frail community-dwelling older adults. Meta-analyses (where possible) with either a fixed- or random- effect(s) model, standardized mean difference (SMD), odds ratio (OR) and tests of heterogeneity were performed. Multivariable meta-regression was performed to identify predictors of statistically significant outcome measures. The risk of bias was assessed using the modified Cochrane Risk-of-Bias tool.
RESULTS: Twenty-two RCTs with 900 participants in the experimental group and 1015 participants in the control group were included. When compared to minimal intervention, community-based exercises significantly improved lower limb strength (10 RCTs, 384 participants in the experimental group and 482 participants in the control group) with SMD 0.67 (95% CI 0.29 to 1.04), and lower limb function (5 RCTs, 120 participants in the experimental group and 219 participants in the control group) with SMD 0.27 (95% CI 0.03 to 0.51). Those who have received community-based exercises were more likely to reverse from pre-frailty to healthy state (OR = 2.74, 95% CI 1.36 to 5.51) (6 RCTs, 263 participants in the experimental group and 281 participants in the control group). The frequency of exercise sessions was a significant predictor of the effect size for gait speed (P<0.05).
CONCLUSIONS: Community-based exercise intervention is superior to minimal intervention for improving health status in pre-frail older adults. This has implications on the implementation of community-based exercise intervention by healthcare providers and policymakers.
OTHER: Nil funding for this review. PROSPERO registration number CRD42022348556.
Despite the rapid development of tumor markers and liver imaging, pathological confirmation is still necessary for atypical liver lesions that do not meet imaging criteria. US guided procedures are widely used as a method to identify focal lesions of the liver pathologically, and these US guided procedures have no burden on the operation, can be easily accessed, and have a lower cost than surgery. However, the frequency of pathological confirmation with this US guided procedure remains at around 90%. In order to increase this probability, a technique for fusion of liver CT/MRI and US has been widely used in recent years, and this allows accurate targeting of small lesions through structures seen in CT and MR. Through the fusion technique, the biopsy success rate for focal lesions can be increased to 94.4%. However, there are many cases where lesions deeply located in patients with cirrhosis are invisible, and biopsy is difficult only with fusion due to poor sonic window in patients with high BMI. To this end, a technique called contrast-enhanced ultrasonography (CEUS), such as the fusion technique, was added, which is a technique that can identify tumor vascularity in real-time using second-generation contrast media. In recent studies, there are studies combining this fusion technique and CEUS technique, and the success rate of these techniques varies from 87.6% to 97.5%. Although CEUS with fusion techniques are theoretically superior to fusion only technique, the use of CEUS adds cost of contrast media and is limited in patients with side effects on contrast media. . Also, there is no study comparing the two so far, and this study intends to compare the technique combining CEUS and fusion and the technique using only fusion.
RESEARCH QUESTION: What is the influence of biological, technical and clinical factors on embryo outcomes in preimplantation genetic testing for aneuploidies (PGT-A) and what is the recurrence pattern?
DESIGN: This retrospective study included 64,071 embryos undergoing PGT-A in the same laboratory between 2011 and 2019. Biopsies were performed at the day 3 embryo stage (48.32%) or blastocyst stage (51.70%). Advanced maternal age (AMA) was the main indication (65.62%).
RESULTS: The aneuploidy rate was 67.75%, higher in women aged over 35 years than in women aged 35 years or less (71.76% versus 47.44%), and higher in day 3 embryo versus blastocyst biopsies (77.51% versus 58.62%). The trisomy:monosomy ratio was 1.01 for blastocysts versus 0.84 for day 3 embryos. Trisomy 21 was present in 4.9% of embryos. In aneuploid embryos, the probability of having one or more involved chromosomes followed a decreasing exponential pattern. The probability of an embryo being euploid was constant at around 30% (40% in blastocysts, 20% in day 3 embryos). The cumulative probability of having one or more euploid embryos after 10 biopsied embryos was 94.79% in blastocysts and 80.61% in day 3 embryos. AMA was associated with a much higher aneuploidy rate than all other indications, which among them had similar aneuploidy rate and chromosomal involvement.
CONCLUSIONS: There is a considerably lower aneuploidy rate in blastocysts than day 3 embryos, which is most notable for monosomies. While AMA shows an increased aneuploidy rate and a specific chromosomal pattern of involvement, the remaining indications showed a similar aneuploidy rate and chromosomal pattern. Even after producing many consecutive aneuploid embryos, the possibility of obtaining a euploid embryo is not negligible.
Understanding the microbial communities in asymptomatic oil palm seedlings is crucial for developing disease-suppressive microbiota against basal stem rot (BSR) in oil palm. In this study, we compared the microbial communities in bulk soil, rhizosphere, and endosphere of control, asymptomatic, and symptomatic seedlings following inoculation with Ganoderma boninense. Our findings revealed significant shifts in microbial structure and interactions, particularly in asymptomatic seedlings. Both Actinobacteriota and Ascomycota were notably enriched in these samples, with Actinobacteriota identified as keystone taxa. Long-read shotgun metagenomics demonstrated that 67.4% of enriched Actinobacteriota taxa were unique to asymptomatic seedlings. Similarly, Ascomycota members showed significant enrichment, suggesting their potential role in BSR suppression. The consistent identification of these phyla across various analyses underscores their importance in disease resistance. This is the first report detailing the shifts in prokaryotic and fungal communities in asymptomatic and symptomatic seedlings, offering insights into potential disease-suppressive taxa across three compartments: bulk soil, rhizosphere, and endosphere of oil palm seedlings.
Excellent preventives/remedies for inflammatory diseases are provided by using ornithine and/or branched amino acids as the active ingredient. Moreover, a method of treating or preventing inflammatory diseases by using these drugs and utilization of the active ingredients in preventives/remedies for inflammatory diseases are provided. As the amino acids (ornithine and branched amino acids) to be used as the active ingredients, use can be made of not only free amino acids but also salts thereof, if any, and derivatives which can be converted into the amino acids (free amino acids) serving as the active ingredients in vivo. Combined use of ornithine with branched amino acids can establish a particularly enhanced effect.  These ingredients, which have little side effect, are usable in medicines (including transfusions, supplements, etc.) or foods and drinks (including medical foods, health foods, specified health foods, etc.) for treating or preventing diseases such as rheumatoid arthritis, preventing the progress of these diseases or ameliorating the same.
The subject of the invention is a sterile, dehydrated acellular implant, which during its rehydration by water or bodily fluids displays anisotropic expansion and can act as a substrate for adhesion, migration and growth of live cells. Collagen structures of the transplant are at least partially denatured through the action of heat or organic solvents, such as lower aliphatic alcohols and ketones, which simultaneously act as preservative and sterilization agents, especially for certain types of viruses. The implant is sterilized by radiation while in an substantially dehydrated state, preferably by accelerated electrons. The transplant can be derived from various animal tissues, especially mammalian tissues, such as human or porcine tissues. The tissues suitable for the invention can be, for example, skin, placenta, pericardium, peritoneum, intestinal wall, tendon, blood vessel, etc. The implant is suitable for use in human and veterinary medicine, for instance as a temporary wound and burn cover, for the repair, substitution and regeneration of tissues, and also as a substrate for laboratory cell cultivation.